QOL-24. Continuous monitoring of fatigue in patient with glioblastoma

Abstract INTRODUCTION In glioblastoma (GBM), fatigue is a very subjective and widely understudied feeling. This fatigue is particularly important for patient with glioblastoma given their requirement for aggressive treatment and short life expectancy. Several hypotheses may explain the development of fatigue, including direct effect of the tumor or its treatment, concomitant depressive state linked to the altered health status and dysregulation of the autonomic nervous system. We postulate that a combined measure of physical and autonomic activities, acquired through a wearable device will provide robust biomarkers of the clinical and physical evolution, frequency of seizures and fatigue of the patients. METHOD We used a wearable device (Embrace+ smartwatch, EmpaticaÓ) and an electronic diary to monitor daily the fatigue using a Visual Analog Scale (VAS) and seizures of patients. Every 2 to 3 months, patients have their clinical follow up and brain MRI as planned in the routine assessment of patients with GBM. During the clinical follow up, questions about medications and a battery of questionnaires including the Multidimensional Fatigue Inventory (MFI) are completed by the patient. RESULTS As of June 2025, 11/20 patients were enrolled in this trial. Daily values of the VAS have been linked to the “Reduced Motivation” scale of the MFI. Furthermore, patients tend to be less active during days in which they end up feeling more fatigued. More results regarding fatigue and mood, therapy and life expectancy are under investigation. CONCLUSION Our preliminary data strongly suggest that fatigue measured by standardized questionnaires can be anticipated based on the completion of a simple VAS question completed daily by the patient and correlated to continuous activity measures obtained by a wearable device.